Atlas Trials

Venetoclax in Combination With 5 Days Azacitidine in Untreated AML Patients, Not Eligible for Standard Induction Therapy

Clinical trial NCT05833438 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT05833438
Sponsor
University of Leipzig
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Acute Myeloid Leukemia (AML)
Start date
2023-05-17
Primary completion
2025-11-16
Enrollment
45

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.